Research
Hormonal
Retatrutide increased heart rate by up to 6.7 beats/min, which may offset some benefits of weight loss.
Weight loss treatments like retatrutide may have cardiovascular implications that need to be considered.
StrongQualifiesmedium confidence
Consistent with being a GLP-1 receptor agonist, heart rate was increased by up to 6.7 beats/min by retatrutide, which may be detrimental and offset some of the benefits of weight loss.
Why this rating
Based on the phase 2 clinical trial design mentioned in the abstract.
Source
Retatrutide showing promise in obesity (and type 2 diabetes)
Sheila A Doggrell · Expert Opinion on Investigational Drugs · 2023
DOI 10.1080/13543784.2023.2283020
otherCited 14×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →